Coadministration of 5% glucose solution has a decrease in bendamustine-related vascular pain grade

摘要

In several trials, bendamustine (TREANDA?) has demonstrated clinical activity in patients with relapsed rituximab-refractory B-cell non-Hodgkin lymphoma, including those refractory to other alkylating agents. Although bendamustine is infused at a dose of 120mg/m~2 intravenously over 60min on days 1 and 2 every 3 weeks in both Japan and United States, it has been reported that there is a difference in the vascular pain between Japan trial and US trial. In the US trial, there were no reports of vascular pain,meanwhile in the Japanese trial, no grade 2/3/4 vascular pain was observed, but grade 1 vascular pain was noted in 29% over the course of the study.2 However, according to the local side-effects in recent postmarketing reports,3 the effects including infusion site pain (6%), catheter site pain (5%), extravasations, phlebitis, pruritus, irritation, pain and swelling have been reported.